Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Interventional Treatment, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in Primary IgA Nephropathy Patients at Risk of End-stage Renal Disease

NCT01738035 is registered in ClinicalTrials.gov with Calliditas Therapeutics AB as lead sponsor.

NCT NCT01738035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01738035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Interventional Treatment, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in Primary IgA Nephropathy Patients at Risk of End-stage Renal Disease
Lead sponsor
Calliditas Therapeutics AB
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2012
Completion date
September 30, 2015
Enrollment
150 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

primary iga nephropathy